With some of the top clinical and research centers in the U.S., Cedars-Sinai is uniquely positioned at the forefront of translational research to improve Women’s Health:
The Division of Maternal-Fetal Medicine has research programs in understanding determinants of preterm delivery, early placental tissue, safety in childbirth and maternal severe morbidity. Calvin J. Hobel is analyzing the links between psychosocial and prenatal stresses and preterm delivery. The division has established a bio-repository for chorionic villa sampling (CVS) procedures. Cedars-Sinai is the only institution in the nation that stores placental tissue from the first trimester, so that our researchers can investigate the origins of diseases that affect babies and mothers at the earliest stages of pregnancy.
As the Vice Chair of Women’s Health Care Quality and Performance Improvement, Kimberly D. Gregory, MD, MPH has developed Maternal Quality of Care Indicators and linked vaginal birth after cesarean delivery policies on labor and delivery to birth outcomes. She continues to evaluate physician behavior and patient views of delivery as it impacts obstetric outcomes. Sarah J. Kilpatrick, MD, PhD has researched severe maternal morbidity evaluation and potential preventability and continues to work nationally on this area.
Led by Margareta D. Pisarska, MD, the Division of Reproductive Endocrinology & Infertility is researching the process of ovulation to determine why some women experience early menopause. Specific areas of research involve oocyte development, infertility, and abnormalities in reproductive endocrinology, fibroids and premature ovarian failure.
Under the direction of Beth Y. Karlan, MD, the Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute is developing personalized therapeutic approaches to enable targeted attacks on gynecologic and breast cancers.
Sandra Orsulic, PhD, is working to understand the genetic and epigenetic changes leading to the initiation and metastatic spread of ovarian cancer; generate suitable pre-clinical models for testing therapies that target specific biochemical pathways; and identify recognizable histological or molecular markers that could be used for early cancer detection.
Christine Walsh, MD, MS, is studying the genetic changes occurring in ovarian cancer DNA, with the goals of better defining the events that lead to ovarian cancer initiation and progression, and identifying novel therapeutic targets and treatments.
Ilana Cass, MD, is developing programs to educate physicians and patients about end of life care.